Reviewing New Chemicals under the Toxic Substances Control Act Science Issues.

Chemical Review/Search Strategy Meeting .Structure Activity Team (SAT) Meeting development of Exposure/Release Assessments . Conditions of Use, P-Chem, Fate,Health Hazard, Eco Hazard Data & Information PMN Data considered.

Spotlight

SAGE Therapeutics

SAGE Therapeutics is a neuroscience-focused company developing medicines to treat life-threatening, rare CNS disorders. Our mission is to make life better for patients with central nervous systems diseases by discovering, developing, and delivering important new medicines to the market. To achieve that mission we leverage compelling science, a robust clinical foundation, strong partnerships, and a world-class team of founders, advisors, investors, scientists and managers. SAGE’s lead program, SAGE-547, is in clinical development for super-refractory status epilepticus (SRSE) and is the first of many compounds the company is developing in its portfolio of potential seizure medicines.

OTHER WHITEPAPERS
news image

Chemical Logistics Digital connections and positive reactions

whitePaper | April 8, 2020

Digitalization opens the door to a new age for the chemical industry. It paves the way for companies in the industry from material suppliers to solution and service providers. It is the driving force behind development that creates a new level of efficiency and transparency for the industry’s sensitive supply chains.

Read More
news image

Implementing a Successful Oil & Gas Sampling Program

whitePaper | July 15, 2021

With aging equipment and facilities, operators face increasing challenges in maintaining equipment reliability, integrity and safety. One of the biggest hidden threats to efficient and safe operation is deteriorating sampling equipment. However, oil and gas companies often operate sampling systems as separate entities within their systems. This leaves operations open to gaps and potential risks in their sampling system.

Read More
news image

What to Know When Conveying and Feeding Calcium Carbonate in Plastics Compounding

whitePaper | May 11, 2021

This paper outlines the importance of correct design of a conveying and feeding system for calcium carbonate in plastics compounding operations and how it is not a trivial proposition because of the number of variables that affect the flow and different powders.

Read More
news image

Deck 7 Webinars and Virtual Events

whitePaper | January 1, 2020

If you recognize some of these challenges, download the Deck 7 Webinar & Virtual Events overview to see how we make it easy for busy marketers to run highly successful webinars and virtual events....

Read More
news image

Employee Scheduling for Manufacturing: A Best Practices Guide

whitePaper | June 16, 2021

As demand continues to surge for many chemical manufacturers, ensuring adequate staffing to meet daily volume targets is a top-of-mind issue for plant managers. Read the guide to discover the best practices of employee scheduling you can leverage to improve the overall effectiveness of labor resources

Read More
news image

Chemical Innovation Outlook 2020

whitePaper | February 28, 2020

The global chemical industry is today worth over $4.3T and is an integral part of the modern world economy, converting raw materials into products encompassing an enormous variety - from plastics to paints, agri-food, consumer goods, textiles and leather products. Many of these items subsequently form part of other value chains, such as automotive, mechanical engineering and construction.

Read More

Spotlight

SAGE Therapeutics

SAGE Therapeutics is a neuroscience-focused company developing medicines to treat life-threatening, rare CNS disorders. Our mission is to make life better for patients with central nervous systems diseases by discovering, developing, and delivering important new medicines to the market. To achieve that mission we leverage compelling science, a robust clinical foundation, strong partnerships, and a world-class team of founders, advisors, investors, scientists and managers. SAGE’s lead program, SAGE-547, is in clinical development for super-refractory status epilepticus (SRSE) and is the first of many compounds the company is developing in its portfolio of potential seizure medicines.

Events